[The future of methotrexate therapy and other folate inhibitors].
Because of its good effectiveness and tolerability, methotrexate (MTX) has been the most important DMARD for the treatment of rheumatoid arthritis (RA) worldwide for many years. Thus the treatment of this disease is strongly based on the principle of folate inhibition. Recent years have brought new insights into the pharmacology and mechanisms of action of MTX. As a result, it now appears possible to further develop folate inhibitors to increase effectiveness and specificity. Polyglutamation of the drug, a metabolic step which appears to play a role both in terms of therapeutic effects and hepatic side effects, might be a possible starting point. Moreover, methods of targeted drug delivery intended to increase drug accumulation at the site of inflammation can increase the effectiveness of treatment and reduce toxicity. Albumin-coupled and liposomally-conjugated MTX, both of which inhibit inflammation in animal models more potently than MTX, are undergoing preclinical evaluation. It was recognized that activated synovial macrophages upregulate folate receptor ß (FR-ß) expression and that MTX can become active by this pathway. This finding makes it possible to develop new FR-ß-specific folate inhibitors with specificity for this pathophysiologically important cell population.
ACURA Rheumazentrum Baden-Baden, Rotenbachtalstrasse 5, Baden-Baden, Germany. c.fiehn@acura-kliniken.com
C
C
Fiehn
D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D016503:Drug Delivery Systems / Q000379:methods*; D005493:Folic Acid Antagonists / Q000627:therapeutic use*; D005544:Forecasting; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use*; D012219:Rheumatology / Q000639:trends*
D018501:Antirheumatic Agents; D005493:Folic Acid Antagonists; D008727:Methotrexate
Rheumatology (Oxford). 2008 Mar;47(3):249-55
18045808
Clin Pharmacokinet. 1996 Mar;30(3):194-210
8882301
Arthritis Rheum. 2010 Feb;62(2):359-68
20112376
Arthritis Rheum. 2004 Sep;50(9):2766-74
15457444
Ann Rheum Dis. 2005 Aug;64(8):1180-5
15677700
Ann Rheum Dis. 2008 Aug;67(8):1188-91
18408252
Schweiz Med Wochenschr. 1967 Oct 7;97(40):1301-10
4968560
Arthritis Rheum. 2009 Aug;60(8):2248-56
19644853
Arthritis Rheum. 1986 Jul;29(7):832-5
2427090
Br J Rheumatol. 1995 Mar;34(3):241-5
7728399
Rheumatology (Oxford). 2004 Sep;43(9):1097-105
15199219
Clin Exp Immunol. 1995 Dec;102(3):560-5
8536373
Biochem Pharmacol. 2009 Apr 1;77(7):1161-72
19174154
Arthritis Rheum. 2010 Jun;62(6):1803-12
20191581
Rheumatology (Oxford). 2001 Apr;40(4):375-83
11312373
J Immunol. 2003 May 1;170(9):4793-801
12707361
Arthritis Rheum. 2008 Nov;58(11):3299-308
18975321
Arthritis Rheum. 1999 Aug;42(8):1609-16
10446858
J Rheumatol. 2006 May;33(5):862-4
16652417
Arthritis Rheum. 2008 Nov;58(11):3279-82
18975304
Ann Rheum Dis. 1992 May;51(5):600-3
1616322
Ann Rheum Dis. 2004 Jul;63(7):884-6
15194591
Drug Deliv. 2001 Oct-Dec;8(4):231-7
11757781
Clin Exp Rheumatol. 2010 Sep-Oct;28(5 Suppl 61):S40-5
21044432
J Med Chem. 2000 Apr 6;43(7):1253-6
10753462